A clear communicator with training in journalism, biochemistry/biophysics, and content marketing. Skills include long- and short-form writing, interviewing, social media, SEO, and editing.
Kick-starting chemistry careers to improve access
Article for Chemical & Engineering News sponsored by Genentech
Annual workshop empowers chemists from underrepresented groups to thrive in diverse careers.
Should people with PCOS consider inositol as a treatment?
Article for Metabolic Insights, the blog of Levels Health
Inositol has recently gained attention as a potential treatment for polycystic ovarian syndrome (PCOS). Inositol is a naturally occurring molecule that can be taken as a supplement and has been the subject of multiple studies and randomized controlled trials as a remedy for PCOS. This blog covers some of the most important research findings—what inositol is, why people are considering it, how it works, and whether it might be a viable treatment option for PCOS.
Safety, Respect, and Belonging for LGBTQ+ Scientists
Article for Chemical & Engineering News BrandLab sponsored by Pfizer
Specific pressures and power structures in STEM fields create unique challenges and considerations for helping LGBTQ+ people succeed and thrive. This article explores strategies for supporting inclusion in chemistry at Pfizer and beyond.
What Does High-Quality Spatial Genomics Data Look Like?
eBook for Vizgen
Like detective work, detailed understanding of the complexities of biological systems requires scientists to answer questions about details at every level: what, when, why, how…and where. This eBook helps establish data quality metrics for the nascent field of spatial transcriptomics and gives researchers the information they need to compare spatial technology platforms.
Sensitive Molecular Detection for Solid Tumor Oncology
eBook for Bio-Rad Laboratories
This eBook explores how cutting-edge technology is enabling more precise, timely care for solid tumor cancers. Compare and contrast ultra-sensitive molecular methods such as NGS and ddPCR technology that are already driving advancements in therapy monitoring and minimal residual disease (MRD) testing for solid tumors.
With funding dwindling, how can biotech companies maintain momentum?
Article written for Discovery Life Sciences
With a potential recession on the horizon, biotechnology companies are seeing funding sources drying up. Large and small organisations alike must find creative ways to leverage their assets and opportunities to continue moving forward. Partnering with biopharmaceutical outsourcing companies gives drug and diagnostic developers the ability to apply advanced tools for drug discovery, analysis and quality control without making capital investments they cannot afford.
Using ddPCR Technology to Improve Cancer Detection and Treatment Efficacy Monitoring
Blog post for Bio-Rad Laboratories
Cancer remains a leading cause of death worldwide. However, as cancer treatments continue to improve and diagnoses happen sooner, more and more patients are experiencing remission. To further increase survival rates and reduce unnecessary treatment, scientists and clinicians are turning to ultra-sensitive molecular analysis to inform treatment decisions and predict and detect relapse.
Achieving Relevant Preclinical Characterization of CAR T Cell Therapies
Whitepaper for The Jackson Laboratory
To avoid risks and setbacks associated with CAR T therapies, scientists need a preclinical research platform that will deliver fast, reproducible, relevant, and actionable results without endangering human patients. A humanized in vivo platform is ideal for CAR T cell therapy characterization, safety, and efficacy testing.
Insilico Achieves 99% Cost Savings in Drug Candidate Discovery Using AWS
Case study for Amazon Web Services (AWS).
To help biopharma and biotechnology companies streamline and accelerate their drug discovery and development pipelines, Insilico Medicine developed a robust suite of machine learning (ML)-powered tools to aid in target identification, molecule design, and lead optimization.
Improving Preclinical Drug Safety by Evaluating Cytokine Release Syndrome in Humanized Mice
Article for American Pharmaceutical Review on behalf of The Jackson Laboratory
Engrafting human immune systems into mice yields a versatile preclinical platform for generating reproducible, translationally-relevant data about the safety and efficacy of novel therapeutics. With this tool, scientists can evaluate CRS risk, perform dose ranging studies, and observe downstream organ effects of immune responses in a diversified population, giving better predictions of clinical outcomes.
Studying Complex, Systemic Immune Responses in Humanized Mice
Article for The Jackson Laboratory
The Jackson Laboratory (JAX) has developed a versatile toolset of mouse models capable of supporting extensive functional components of the human immune system. These mice provide a preclinical research platform that yields sensitive, reproducible results to screen drug candidates for inflammatory responses. The platform also offers insight into the progression of immune disorders and the potential efficacy of drugs meant to treat them.
Behind the Nature Publication: University of British Columbia Identifies 130,000 New Viruses in 11 Days
Case study for Amazon Web Services (AWS).
Biotechnology data is expanding at a rate exceeding Moore’s law, and experts are increasingly grappling with how to effectively share this data to accelerate scientific breakthroughs. Genomic data sharing leads to more accurate and deeper research insights, but its massive volume can present logistical challenges in areas like security, storage capacity, and global accessibility which can be addressed using Amazon Web Services (AWS).
Q&A: Studying Cytokine Release Syndrome in a Diverse Population
Q&A Blog for The Jackson Laboratory
To understand the future of preclinical drug studies, we sat down with James Keck, Ph.D., who was recently recognized as a JAX President’s Innovation Fellow for his work creating mouse-based platforms to study the immune system and evaluate new therapeutics for both safety and efficacy.
Ctenophore genome assembly combed for evolutionary clues
Blog for Genetics Society of America
Scientists generated a karyotype, chromosome-scale genome assembly, and manual genome annotation for a common ctenophore.
A New Way to Study Cytokine Release Syndrome
White paper for The Jackson Laboratory
Your odds of failing a clinical trial due to safety or efficacy shouldn’t be the same as flipping a coin. A CRS Evaluation Study significantly improves your odds of success with data that paints a clinically relevant, holistic picture of patient response much earlier in the drug development pipeline.